PURPOSE: Metronomic chemotherapy regimens have shown anti-tumor activity by anti-angiogenic mechanisms, however, the efficacy of metronomic topotecan in ovarian cancer is not known and the focus of the current study. EXPERIMENTAL DESIGN: In vivo dose-finding and therapy experiments with oral metronomic topotecan were performed in an orthotopic model of advanced ovarian cancer. Tumor vascularity (MVD: CD31), proliferation (PCNA) and apoptosis (TUNEL) were examined among treatment arms. In vitro experiments including MTT and western blot analysis were performed to identify specific anti-angiogenic mechanisms of topotecan. RESULTS: Compared to controls, metronomic (0.5, 1.0 and 1.5 mg/kg; daily) and maximum tolerated therapy (MTD; 7.5 and 15 mg/kg; weekly) dosing regimens reduced tumor growth in dose-finding experiments, but significant morbidity and mortality was observed with higher doses. Metronomic and MTD topotecan therapy significantly reduced tumor growth in both HeyA8 and SKOV3ip1 models: 41-74% (metronomic), and 64-86% (MTD dosing) (p < 0.05 for both regiments compared to controls). Compared to controls, the greatest reduction in tumor MVD was noted with metronomic dosing (32-33%; p < 0.01). Tumor cell proliferation was reduced (p < 0.001 vs. controls) and apoptosis increased in all treatment arms (p < 0.01 vs. controls) for both dosing regimens. Endothelial cells demonstrated a significantly higher sensitivity to topotecan using metronomic dosing versus MTD in vitro. Pro-angiogenic regulators Hif-1alpha and VEGF levels were reduced in vitro (HeyA8 and SKOV3ip1) with topotecan independent of proteasome degradation and topoisomerase I. CONCLUSION: Metronomic topotecan may be a novel therapeutic strategy for ovarian carcinoma with significant anti-tumor activity and target modulation of key pro-angiogenic mediators.
PURPOSE: Metronomic chemotherapy regimens have shown anti-tumor activity by anti-angiogenic mechanisms, however, the efficacy of metronomic topotecan in ovarian cancer is not known and the focus of the current study. EXPERIMENTAL DESIGN: In vivo dose-finding and therapy experiments with oral metronomic topotecan were performed in an orthotopic model of advanced ovarian cancer. Tumor vascularity (MVD: CD31), proliferation (PCNA) and apoptosis (TUNEL) were examined among treatment arms. In vitro experiments including MTT and western blot analysis were performed to identify specific anti-angiogenic mechanisms of topotecan. RESULTS: Compared to controls, metronomic (0.5, 1.0 and 1.5 mg/kg; daily) and maximum tolerated therapy (MTD; 7.5 and 15 mg/kg; weekly) dosing regimens reduced tumor growth in dose-finding experiments, but significant morbidity and mortality was observed with higher doses. Metronomic and MTD topotecan therapy significantly reduced tumor growth in both HeyA8 and SKOV3ip1 models: 41-74% (metronomic), and 64-86% (MTD dosing) (p < 0.05 for both regiments compared to controls). Compared to controls, the greatest reduction in tumor MVD was noted with metronomic dosing (32-33%; p < 0.01). Tumor cell proliferation was reduced (p < 0.001 vs. controls) and apoptosis increased in all treatment arms (p < 0.01 vs. controls) for both dosing regimens. Endothelial cells demonstrated a significantly higher sensitivity to topotecan using metronomic dosing versus MTD in vitro. Pro-angiogenic regulators Hif-1alpha and VEGF levels were reduced in vitro (HeyA8 and SKOV3ip1) with topotecan independent of proteasome degradation and topoisomerase I. CONCLUSION: Metronomic topotecan may be a novel therapeutic strategy for ovarian carcinoma with significant anti-tumor activity and target modulation of key pro-angiogenic mediators.
Authors: Marjorie C Green; Aman U Buzdar; Terry Smith; Nuhad K Ibrahim; Vicente Valero; Marguerite F Rosales; Massimo Cristofanilli; Daniel J Booser; Lajos Pusztai; Edgardo Rivera; Richard L Theriault; Cynthia Carter; Debra Frye; Kelly K Hunt; W Fraser Symmans; Eric A Strom; Aysegul A Sahin; William Sikov; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Annamaria Rapisarda; Jessica Zalek; Melinda Hollingshead; Till Braunschweig; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Stephen M Hewitt; Robert H Shoemaker; Giovanni Melillo Journal: Cancer Res Date: 2004-10-01 Impact factor: 12.701
Authors: A D Seidman; C A Hudis; J Albanell; J Albanel; W Tong; I Tepler; V Currie; M E Moynahan; M Theodoulou; M Gollub; J Baselga; L Norton Journal: J Clin Oncol Date: 1998-10 Impact factor: 44.544
Authors: William M Merritt; Alpa M Nick; Amy R Carroll; Chunhua Lu; Koji Matsuo; Melissa Dumble; Nicholas Jennings; Shuyun Zhang; Yvonne G Lin; Whitney A Spannuth; Aparna A Kamat; Rebecca L Stone; Mian M K Shahzad; Robert L Coleman; Rakesh Kumar; Anil K Sood Journal: Mol Cancer Ther Date: 2010-04-06 Impact factor: 6.261
Authors: David C Turner; Todd D Tillmanns; K Elaine Harstead; Stacy L Throm; Clinton F Stewart Journal: Anticancer Res Date: 2013-09 Impact factor: 2.480
Authors: Kshipra M Gharpure; Kevin S Chu; Charles J Bowerman; Takahito Miyake; Sunila Pradeep; Selanere L Mangala; Hee-Dong Han; Rajesha Rupaimoole; Guillermo N Armaiz-Pena; Tojan B Rahhal; Sherry Y Wu; J Christopher Luft; Mary E Napier; Gabriel Lopez-Berestein; Joseph M DeSimone; Anil K Sood Journal: Mol Cancer Ther Date: 2014-04-22 Impact factor: 6.261
Authors: Rebecca A Previs; Guillermo N Armaiz-Pena; Yvonne G Lin; Ashley N Davis; Sunila Pradeep; Heather J Dalton; Jean M Hansen; William M Merritt; Alpa M Nick; Robert R Langley; Robert L Coleman; Anil K Sood Journal: Mol Cancer Ther Date: 2015-10-29 Impact factor: 6.261
Authors: M Frumovitz; M F Munsell; J K Burzawa; L A Byers; P Ramalingam; J Brown; R L Coleman Journal: Gynecol Oncol Date: 2016-11-04 Impact factor: 5.482